Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

119M-1

Sigma-Aldrich

CD19 (MRQ-36) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-36, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (119M-14)
vial of 0.5 mL concentrate (119M-15)
bottle of 1.0 mL predilute (119M-17)
vial of 1.0 mL concentrate (119M-16)
bottle of 7.0 mL predilute (119M-18)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

isotype

IgG1κ

control

tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

membranous

Gene Information

human ... CD19(930)

Related Categories

General description

CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.

Quality


IVD
IVD
IVD
RUO

Linkage

CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S A Greenberg et al.
Neurology, 65(11), 1782-1787 (2005-12-14)
Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Microarray studies were performed on muscle biopsy
Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
N Masir et al.
Histopathology, 48(3), 239-246 (2006-01-25)
To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. A polyclonal antibody to the C terminus of CD19 was used to immunostain

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service